Quick Takeaways: Why It Matters? Loyal’s completion of the RXE efficacy requirement for LOY‑003 means all three of its canine longevity candidates (LOY‑001, LOY‑002, LOY‑003) have now met the FDA’s efficacy bar under the Expanded Conditional Approval pathway, putting the compan...
Quick Takeaways Why It Matters? Loyal’s raise reinforces longevity as a serious, institution-backed frontier in veterinary medicine, moving it from niche concept to an emerging preventive care category. If LOY-002 secures conditional and then full approval, it could...
Quick Takeaways: Why It Matters? With both TAS and RXE accepted, Loyal moves significantly closer to commercializing the first true longevity drug in veterinary medicine, turning canine lifespan extension into a near-term, rather than speculative, market. If LOY-002 reache...
